#SK Biopharmaceuticals announced on the 31st that Cenobamate, a new epilepsy drug, has obtained sales permission from the EC on the 30th (local time).

It has been about two months since it received a recommendation for marketing approval from CHMP under the European Medicines Agency (EMA) last month. Through this sales permit, SK Biopharm has secured a total of 1232.2 million dollars (about 140 billion won) worth of technology fees from partners. In addition to the $110 million milestone for European permits received from Angelini Pharma, which is responsible for local sales in Europe, the company will receive an additional $13.22 million milestone for each phase from the sale of its first contract partner